Zhejiang Orient Gene Biotech Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Xiaoliang Fang
Chief executive officer
CN¥907.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | n/a |
| Management average tenure | 7.8yrs |
| Board average tenure | 1.8yrs |
CEO
Xiaoliang Fang (67 yo)
7.8yrs
Tenure
CN¥907,200
Compensation
Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 7.8yrs | CN¥907.20k | no data | |
| Deputy GM & Financial Manager | 7.8yrs | CN¥890.30k | 0.078% CN¥ 4.6m | |
| Deputy General Manager | 7.8yrs | CN¥729.60k | 0.078% CN¥ 4.6m | |
| Deputy General Manager | 7.8yrs | CN¥834.60k | 0.078% CN¥ 4.6m | |
| Deputy General Manager | 7.8yrs | CN¥737.30k | 0.078% CN¥ 4.6m | |
| Deputy General Manager | 7.8yrs | CN¥730.30k | 0.078% CN¥ 4.6m | |
| Accounting Supervisor | no data | no data | no data |
7.8yrs
Average Tenure
51yo
Average Age
Experienced Management: 688298's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 7.8yrs | CN¥907.20k | no data | |
| Chairman | 7.8yrs | CN¥1.47m | no data | |
| Independent Director | 1.5yrs | CN¥33.70k | no data | |
| Vice Chairman | 1.9yrs | no data | no data | |
| Independent Director | 1.8yrs | no data | no data | |
| Independent Director | 1.8yrs | no data | no data | |
| Employee Representative Supervisor | 1.8yrs | no data | no data | |
| Supervisor | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
50.5yo
Average Age
Experienced Board: 688298's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 04:23 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Orient Gene Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yiling Chen | Guosen Securities Co., Ltd. |
| Hanqing Zhu | Guosen Securities Co., Ltd. |